Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation.

摘要

"USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR ATRIAL FIBRILATION PROPHILAXY OR TREATMENT". The invention relates to the use of a 5-HT receptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodeling in a mammal. Preferably, the antagonist is N - [(1- {n-butyl-4-piperidinyl) methyl] -3,4-dihydro-2H- [1,3] oxazine [3,2-a] indol-10-carb oxamide (SB 207266) or a pharmaceutically acceptable salt thereof. The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of atrial fibrillation in a mammal by administering to the mammal a daily oral or parenteral dosage regimen of approximately 0.2 mg to 1.0 mg of SB 207266 or a salt thereof per kg of total body weight (measured as the free base). The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof for prophylaxis or treatment of atrial arrhythmia in a mammal by administering SB 207266 or a salt thereof on the first day at a loading dose of approximately 1.2 to approximately 2.0 times the daily maintenance dose, followed by administration of SB 207266 or salt at the daily maintenance dose on subsequent days.